1. Home
  2. FLNG vs CSTL Comparison

FLNG vs CSTL Comparison

Compare FLNG & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FLEX LNG Ltd.

FLNG

FLEX LNG Ltd.

HOLD

Current Price

$26.48

Market Cap

1.4B

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$32.37

Market Cap

940.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLNG
CSTL
Founded
2006
2007
Country
Bermuda
United States
Employees
N/A
823
Industry
Marine Transportation
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
940.8M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
FLNG
CSTL
Price
$26.48
$32.37
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$23.00
$46.67
AVG Volume (30 Days)
348.1K
424.7K
Earning Date
02-11-2026
02-26-2026
Dividend Yield
11.35%
N/A
EPS Growth
7.64
N/A
EPS
1.82
N/A
Revenue
$351,034,000.00
$343,530,000.00
Revenue This Year
N/A
$2.88
Revenue Next Year
$3.52
N/A
P/E Ratio
$14.53
N/A
Revenue Growth
N/A
10.15
52 Week Low
$19.46
$14.59
52 Week High
$27.67
$44.28

Technical Indicators

Market Signals
Indicator
FLNG
CSTL
Relative Strength Index (RSI) 55.90 26.17
Support Level $25.88 $31.64
Resistance Level $26.71 $40.88
Average True Range (ATR) 0.58 1.96
MACD -0.05 -1.09
Stochastic Oscillator 54.20 5.89

Price Performance

Historical Comparison
FLNG
CSTL

About FLNG FLEX LNG Ltd.

Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Share on Social Networks: